LNA Santé Valuation
Is LNA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of LNA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: LNA (€23.1) wird über unserer Schätzung des Fair Value (€11.83) gehandelt.
Deutlich unter dem Marktwert: LNA über unserer Schätzung des beizulegenden Zeitwerts gehandelt wird.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LNA?
Other financial metrics that can be useful for relative valuation.
| What is LNA's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | €204.54m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.4x |
| Enterprise Value/EBITDA | 12.4x |
| PEG Ratio | 0.9x |
Price to Earnings Ratio vs Peers
How does LNA's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 17x | ||
BLC Bastide Le Confort Médical | 9.6x | 31.7% | €109.5m |
EQS Equasens Société anonyme | 17.1x | 5.6% | €831.3m |
1526 Rici Healthcare Holdings | 4.4x | n/a | HK$1.7b |
CMR Chiang Mai Ram Medical Business | 37x | n/a | ฿8.1b |
LNA LNA Santé | 8.5x | 9.4% | €204.5m |
Price-To-Earnings gegen Gleichaltrige: LNA ist ein guter Wert, wenn man sein Price-To-Earnings Verhältnis (8.6x) mit dem Durchschnitt der anderen Unternehmen (16.8x) vergleicht.
Price to Earnings Ratio vs Industry
How does LNA's PE Ratio compare vs other companies in the European Healthcare Industry?
Price-To-Earnings gegen Industrie: LNA ist aufgrund seines Price-To-Earnings Verhältnisses (7.4x) im Vergleich zum European Healthcare Branchendurchschnitt (16.8x) ein guter Wert.
Price to Earnings Ratio vs Fair Ratio
What is LNA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 8.5x |
| Fair PE Ratio | 13.3x |
PM vs. Fair Ratio: LNA ist ein guter Wert auf der Grundlage des Verhältnisses Price-To-Earnings (7.4x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Earnings (12x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €20.00 | €32.50 +62.5% | 16.9% | €38.00 | €27.00 | n/a | 2 |
| Mar ’25 | €22.20 | €29.67 +33.6% | 20.3% | €38.00 | €24.00 | n/a | 3 |
| Feb ’25 | €19.56 | €32.67 +67.0% | 18.9% | €38.00 | €24.00 | n/a | 3 |
| Jan ’25 | €20.10 | €35.50 +76.6% | 6.4% | €38.00 | €32.50 | n/a | 3 |
| Dec ’24 | €18.94 | €35.50 +87.4% | 6.4% | €38.00 | €32.50 | n/a | 3 |
| Nov ’24 | €21.15 | €36.17 +71.0% | 8.5% | €40.00 | €32.50 | n/a | 3 |
| Oct ’24 | €24.70 | €36.17 +46.4% | 8.5% | €40.00 | €32.50 | n/a | 3 |
| Sep ’24 | €29.15 | €37.33 +28.1% | 5.1% | €40.00 | €36.00 | n/a | 3 |
| Aug ’24 | €29.05 | €37.33 +28.5% | 5.1% | €40.00 | €36.00 | n/a | 3 |
| Jul ’24 | €28.80 | €37.33 +29.6% | 5.1% | €40.00 | €36.00 | n/a | 3 |
| Jun ’24 | €27.90 | €37.33 +33.8% | 5.1% | €40.00 | €36.00 | n/a | 3 |
| May ’24 | €31.80 | €37.33 +17.4% | 5.1% | €40.00 | €36.00 | n/a | 3 |
| Apr ’24 | €33.40 | €37.33 +11.8% | 5.1% | €40.00 | €36.00 | €20.45 | 3 |
| Mar ’24 | €29.20 | €42.33 +45.0% | 15.0% | €51.00 | €36.00 | €22.20 | 3 |
| Feb ’24 | €31.20 | €42.33 +35.7% | 15.0% | €51.00 | €36.00 | €19.56 | 3 |
| Jan ’24 | €29.60 | €42.33 +43.0% | 15.0% | €51.00 | €36.00 | €20.10 | 3 |
| Dec ’23 | €27.20 | €42.33 +55.6% | 15.0% | €51.00 | €36.00 | €18.94 | 3 |
| Nov ’23 | €30.15 | €44.33 +47.0% | 14.1% | €51.00 | €36.00 | €21.15 | 3 |
| Oct ’23 | €28.90 | €44.33 +53.4% | 14.1% | €51.00 | €36.00 | €24.70 | 3 |
| Sep ’23 | €29.40 | €52.50 +78.6% | 16.6% | €63.00 | €42.00 | €29.15 | 4 |
| Aug ’23 | €33.30 | €52.50 +57.7% | 16.6% | €63.00 | €42.00 | €29.05 | 4 |
| Jul ’23 | €33.70 | €53.50 +58.8% | 15.2% | €63.00 | €42.00 | €28.80 | 4 |
| Jun ’23 | €37.50 | €54.88 +46.3% | 14.4% | €63.00 | €42.00 | €27.90 | 4 |
| May ’23 | €35.00 | €54.88 +56.8% | 14.4% | €63.00 | €42.00 | €31.80 | 4 |
| Apr ’23 | €35.40 | €51.50 +45.5% | 19.0% | €63.00 | €38.00 | €33.40 | 5 |
Analysten-Prognose: Das Kursziel liegt mehr als 20% über dem aktuellen Aktienkurs, aber es gibt nicht genügend Analysten, die die Aktie beobachten, um eine statistische Sicherheit für eine Übereinstimmung zu ermitteln.